These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 27375231)

  • 1. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
    Martinot-Peignoux M; Lapalus M; Maylin S; Boyer N; Castelnau C; Giuily N; Pouteau M; Moucari R; Asselah T; Marcellin P
    J Viral Hepat; 2016 Nov; 23(11):905-911. PubMed ID: 27375231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
    Boyd A; Piroth L; Maylin S; Maynard-Muet M; Lebossé F; Bouix C; Lascoux-Combe C; Mahjoub N; Girard PM; Delaugerre C; Carrat F; Lacombe K; Miailhes P
    J Viral Hepat; 2016 Dec; 23(12):1017-1026. PubMed ID: 27486094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H
    Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B.
    Vecchi A; Rossi M; Tiezzi C; Fisicaro P; Doselli S; Gabor EA; Penna A; Montali I; Ceccatelli Berti C; Reverberi V; Montali A; Fletcher SP; Degasperi E; Sambarino D; Laccabue D; Facchetti F; Schivazappa S; Loggi E; Coco B; Cavallone D; Rosselli Del Turco E; Massari M; Pedrazzi G; Missale G; Verucchi G; Andreone P; Brunetto MR; Lampertico P; Ferrari C; Boni C
    Gut; 2024 Sep; 73(10):1737-1748. PubMed ID: 39033025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
    Marcellin P; Ahn SH; Ma X; Caruntu FA; Tak WY; Elkashab M; Chuang WL; Lim SG; Tabak F; Mehta R; Petersen J; Foster GR; Lou L; Martins EB; Dinh P; Lin L; Corsa A; Charuworn P; Subramanian GM; Reiser H; Reesink HW; Fung S; Strasser SI; Trinh H; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HL;
    Gastroenterology; 2016 Jan; 150(1):134-144.e10. PubMed ID: 26453773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
    Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
    Stelma F; van der Ree MH; Jansen L; Peters MW; Janssen HLA; Zaaijer HL; Takkenberg RB; Reesink HW
    J Viral Hepat; 2017 Dec; 24(12):1107-1113. PubMed ID: 28632898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
    Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
    Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H; Yang RF; Wei L
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.
    Goulis I; Karatapanis S; Akriviadis E; Deutsch M; Dalekos GN; Raptopoulou-Gigi M; Mimidis K; Germanidis G; Drakoulis C; Triantos C; Zintzaras E; Bakalos G; Papatheodoridis G
    Liver Int; 2015 May; 35(5):1540-8. PubMed ID: 25368957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
    Chuaypen N; Posuwan N; Chittmittraprap S; Hirankarn N; Treeprasertsuk S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Clin Microbiol Infect; 2018 Mar; 24(3):306.e7-306.e13. PubMed ID: 28750917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.
    Sonneveld MJ; Arends P; Boonstra A; Hansen BE; Janssen HL
    J Hepatol; 2013 May; 58(5):898-903. PubMed ID: 23376362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.